Herein, it is important to note that the mutation rate of several of these genes in the New EPOC cohort is not representative of the real-world population of patients with liver-metastatic CRC, as the wild-type status of KRAS exon-2 (codons 12, 13, and 61) was a prerequisite for trial eligibility, posing a limitation to our study. Here, KRAS is linked to colorectal carcinoma.